Form 4: Amgen EVP Esteban Santos Equity Grant Disclosure
Statement of Changes in Beneficial Ownership
Amgen EVP of Operations Esteban Santos received a grant of 2,730 restricted stock units and 17,814 stock options.
Summary
- Esteban Santos, EVP of Operations at Amgen, was granted 2,730 Restricted Stock Units (RSUs) on May 5, 2026.
- The RSUs vest in four equal annual installments of 25% starting May 5, 2027.
- A grant of 17,814 non-qualified stock options was issued with an exercise price of $329.59, vesting in four equal annual installments starting May 5, 2027.
- 427 shares were withheld by the company on May 6, 2026, to satisfy tax obligations related to the equity transaction.
- Following these transactions, the reporting person holds 83,369 shares directly and 909.9906 shares indirectly via a 401K plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding executive compensation with no impact on company fundamentals.
Positives
- Alignment of executive interests with long-term shareholder value through multi-year vesting schedules.
- Standard equity incentive structure consistent with corporate governance best practices.
Negatives
- None identified; this is a routine disclosure of executive compensation.
Risks
- None identified; this is a routine disclosure of executive compensation.
Future Outlook
The equity grants are subject to a four-year vesting schedule, indicating management's long-term commitment to the company's operational performance.
Management Comments
- No narrative comments provided; this is a standard regulatory disclosure.
Industry Context
StockSavvy.ai notes that routine equity grants to high-level executives are standard practice in the biopharmaceutical industry to ensure retention and performance alignment.
Comparison to Industry Standards
- The use of four-year vesting schedules for equity awards is consistent with standard compensation practices among large-cap pharmaceutical companies like Pfizer, Merck, and Gilead.
Stakeholder Impact
- Minimal impact on shareholders as these are standard compensation-related equity grants.
Next Steps
- Vesting of equity awards to commence on May 5, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/05/2026 | Date of grant for RSUs and stock options. |
| 05/06/2026 | Date of tax withholding transaction and filing date. |
| 05/05/2027 | Commencement of vesting for RSUs and stock options. |
| 05/05/2036 | Expiration date for non-qualified stock options. |
Keywords
Amgen, AMGN, Form 4, Insider Trading, Executive Compensation, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.